Palomid 529 | Akt/mTOR inhibitor | Axon Medchem | Axon 1718

	Chemistry Service Platform - CRO in Medicinal Chemistry × close
Axon Ligands (TM) - alphabetic: [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z]

Palomid 529

P529

CAS 914913-88-5

C24H22O6 MW 406.43

Purity: 98%

Soluble in DMSO to 100 mM

Ordering Information:

Cat. No. Axon 1718 Prime Source

Qty1: 5 mg (research sample) / 115 $150

Promotion: 2 x 5 mg / 160 $208

Qty2: 25 mg (research sample) / 365 $475

Promotion: 2 x 25 mg / 520 $676

Qty3: on request

Send enquiry to: order@axonmedchem.com

or by fax to: +31-50-3600390.

Biological Activity:

Small molecule kinase inhibitor, targeting Akt/mTOR; Dual TORC1/2 inhibitor of the PI3K/Akt//mTOR pathway having broad activity in angiogenesis and cellular proliferation; P529 inhibits cell growth of a broad spectrum of cancer cell lines.

References:

Q Xue et al. Palomid 529, a Novel Small-Molecule Drug, Is a TORC1/TORC2 Inhibitor That Reduces Tumor Growth, Tumor Angiogenesis, and Vascular Permeability. Cancer Res. 2008, 68(22), 9551-9557. [online]

R Diaz et al. The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer. Br. J. Cancer 2009, 100, 932940. [online]

GL Gravina et al. The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells. Endocr. Relat. Cancer. 2011, 18(4), 385-400. [online]

Chemical Name: 8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one

Palomid 529 | Akt/mTOR inhibitor | Axon Medchem | Axon 1718 | P529